Last updated: 2026-07-23

References — Synthetic Biology

Research date anchor: 2026-07-23. Prefer primary org pages, regulator releases, and peer-review milestones. Secondary journalism used for chronology and contrarian framing.

DNA, genes, proteins (foundational)

  • Standard molecular biology framework: central dogma, genetic code universality — textbooks / NCBI educational materials (background).
  • Sickle-cell molecular classic and CRISPR fetal-hemoglobin strategy — see FDA Casgevy materials below.

Gene sequencing

  • NHGRI — DNA Sequencing Costs Data: https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data
  • NHGRI history / HGP context: https://www.genome.gov/about-nhgri/Brief-History-Timeline
  • Illumina NovaSeq X positioning (~$200 genome, high throughput claims): https://www.illumina.com/systems/sequencing-platforms/novaseq-x-plus/applications/transition.html
  • Illumina news example (20k genomes/year, $200 framing): https://emea.illumina.com/company/news-center/press-releases/2023/4b48580b-42d4-419b-8512-5adcbb069836.html
  • Front Line Genomics — $100 genome discussion (2026 feature): https://frontlinegenomics.com/the-100-genome-wheres-the-limit/

Gene editing / Casgevy

  • FDA — Approves first gene therapies for sickle cell; Casgevy CRISPR note (2023-12-08): https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
  • STAT, BioPharma Dive, TIME, CNBC contemporary coverage of Casgevy approval (Dec 2023) — chronology and pricing context.

Synthetic cells (JCVI)

  • JCVI — First minimal synthetic bacterial cell (syn3.0): https://www.jcvi.org/research/first-minimal-synthetic-bacterial-cell
  • JCVI media — syn3.0 announcement archive (2016-03-24): https://www.jcvi.org/media-center/first-minimal-synthetic-bacterial-cell-designed-and-constructed-scientists-venter
  • Hutchison et al., Science 2016 — Design and synthesis of a minimal bacterial genome (syn3.0).
  • Gibson / Venter lineage — syn1.0 Science 2010 — Creation of a bacterial cell controlled by a chemically synthesized genome.

Colossal / de-extinction

  • Colossal — Dire wolf project page: https://colossal.com/direwolf/
  • Colossal — De-extinction overview: https://colossal.com/de-extinction/
  • Colossal — Mammoth project: https://colossal.com/mammoth/
  • Science — “Is the dire wolf back from the dead? Not exactly” (2025-04-08): https://www.science.org/content/article/dire-wolf-back-dead-not-exactly
  • High Country News — de-extinction critique / IUCN canid specialist quotes: https://www.hcn.org/articles/de-extinction-isnt-real-but-the-conservation-questions-it-raises-are/
  • NPR — mammoth / dire wolf reporting (2026-03-04): https://www.npr.org/2026/03/04/nx-s1-5704318/colossal-woolly-mammoth-dire-wolf
  • X / @colossal primary social updates (2025–2026) — treat as company voice; verify against scientific literature for taxonomic claims.
  • PMC ethical analysis of dire wolf claims (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12248547/

United Therapeutics / xenotransplantation

  • UTHR — FDA IND clearance UKidney (2025-02-03): https://ir.unither.com/press-releases/2025/02-03-2025-120011819
  • UTHR — First EXPAND transplant (2025-11-03): https://ir.unither.com/press-releases/2025/11-03-2025-120022270
  • NYU Langone — First gene-edited pig kidney clinical trial surgery: https://nyulangone.org/news/first-gene-edited-pig-kidney-transplant-clinical-trial-begins-nyu-langone-health
  • ClinicalTrials.gov — EXPAND / UKidney (NCT06878560).
  • Nature Medicine news — pig kidney trials turning point (2025-03-18): https://www.nature.com/articles/d41591-025-00020-0
  • UTHR pipeline page: https://pipeline.unither.com/
  • PMC — EXPAND study description: https://pmc.ncbi.nlm.nih.gov/articles/PMC12728669/

Longevity / partial reprogramming

  • Life Biosciences site: https://www.lifebiosciences.com/
  • Life Biosciences — ARDD 2025 PER platform data: https://www.lifebiosciences.com/life-biosciences-presents-new-data-at-ardd-2025-on-the-companys-partial-epigenetic-reprogramming-platform-in-liver-and-ocular-diseases/
  • Longevity.Technology / Endpoints / Fortune — Jan 2026 FDA path for ER-100 (see Life Bio media page): https://www.lifebiosciences.com/news/in-the-media/
  • Technology Networks interview on ER-100 (2026): https://www.technologynetworks.com/biopharma/articles/re-setting-the-epigenetic-clock-to-reverse-cellular-aging-413392
  • Prior OOM package: ../longevity-research/ (2026-04-12).

Alternative proteins

  • GFI-style industry trackers and company approvals (background; verify per jurisdiction).
  • Market sizing vendors (Mordor etc.) — directional only for synbio/food crossover: https://www.mordorintelligence.com/industry-reports/synthetic-biology-market
  • AI protein design market notes (directional): DataM / vendor benchmarks 2025–2026.

Vertical farming / CEA

  • CEAg World — vertical farming paradox (demand vs investment, 2025): https://www.ceagworld.com/vertical-farming/vertical-farmings-paradox-growth-in-demand-decline-in-investment/
  • Ageye — CEA 2025 year in review / 2026 outlook: https://ageyetech.com/news/cea-industry-2025-review-vertical-farming-outlook-2026/
  • AgFunderNews — energy priority in CEA census: https://agfundernews.com/renewable-energy-now-a-top-priority-for-indoor-agriculture-report
  • Eutrema — UK 2026 standing charge shock: https://eutrema.co.uk/uk-vertical-farms-face-a-major-energy-cost-shock-in-2026/
  • Case references to Bustanica-scale farms in secondary economic papers (water savings claims).

Market / convergence (use cautiously)

  • Mordor Intelligence — Synthetic Biology Market (accessed 2026 research window): USD figures are vendor estimates, not primary accounting.
  • AI protein design market reports — same caveat.

Source-quality caveats

  • Private valuation rumors for Colossal (e.g. social discussion of multi-ten-billion valuations in 2026) are weak unless confirmed by reputable deal desk reporting.
  • Illumina “$200 genome” is list/reagent-framed marketing economics, not universal hospital pricing.
  • De-extinction species identity is contested; company pages and critical science press must be read together.
  • Longevity social media claims of multi-decade age reversal from early trials are not treated as evidence.

Internal cross-references

  • ../longevity-research/index.md
  • OOM taxonomy: Synthetic Biology, Gene Sequencing, Genetic Engineering, Alternative Proteins
← RisksQuestion ledger →